MEI Pharma (NASDAQ:MEIP) Research Coverage Started at assumed coverage on shares of MEI Pharma (NASDAQ:MEIPGet Free Report) in a research note issued to investors on Friday. The brokerage set a “buy” rating on the stock.

A number of other research analysts have also recently issued reports on MEIP. TheStreet cut shares of MEI Pharma from a “c-” rating to a “d+” rating in a research note on Thursday, February 1st. Stifel Nicolaus restated a “hold” rating and set a $7.00 target price on shares of MEI Pharma in a research report on Friday, April 12th.

Read Our Latest Research Report on MEI Pharma

MEI Pharma Stock Performance

Shares of MEIP stock opened at $2.90 on Friday. The firm’s 50-day moving average is $3.36 and its 200-day moving average is $4.61. MEI Pharma has a 52-week low of $2.87 and a 52-week high of $7.87. The stock has a market cap of $19.31 million, a price-to-earnings ratio of 0.74 and a beta of 0.82.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in MEI Pharma stock. National Bank of Canada FI bought a new position in MEI Pharma, Inc. (NASDAQ:MEIPFree Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 6,000 shares of the company’s stock, valued at approximately $36,000. National Bank of Canada FI owned about 0.09% of MEI Pharma as of its most recent SEC filing. Hedge funds and other institutional investors own 52.38% of the company’s stock.

MEI Pharma Company Profile

(Get Free Report)

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.

See Also

Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with's FREE daily email newsletter.